Our Approach


Our pipleline includes drugs aimed at first-in-class targets that are synthetically lethal with the loss of the following metabolic enzymes: Fumarate Hydratatse (FH), Succinate Dhydrogenase (SDH) and Methylthioadenosine Phosphorylase (MTAP). Although SDH and FH are “housekeeping genes”‘ with key bioenergetic roles, they are also known to be tumor-suppressing genes. The loss of their function results in cancer, specifically in the kidney and in the GI tract. MTAP function is lost in about 15% of all cancers. This percentage grows to 55% of Glioblastoma and up to 25% Pancreatic Adenocarcinoma, two especially aggressive and hard to treat cancers.

Program Discovery Preclinical Clinical
  • IE/Hypoxia  
  • SL/SDH  
  • SL/MTAP  
  • SL/FH  

We are also developing drugs targeting induced metabolic vulnerabilities in tumors characterized by metabolic stress, such as hypoxia.